A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Tuen Mun Hospital
Bristol-Myers Squibb
N.N. Alexandrov National Cancer Centre
N.N. Alexandrov National Cancer Centre
Hoffmann-La Roche
Federation Francophone de Cancerologie Digestive
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Jiangsu HengRui Medicine Co., Ltd.
AbbVie
Sun Yat-sen University
Seattle Project Corporation